Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Hypertensive Urgency, Weather
Phase Not Applicable
Enrollment 350
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

relationship between the onset times of symptoms and the regions of patients presenting to the emergency department with hypertensive crisis (systolic ≥180 and/or diastolic ≥110 mmHg) and the fluctuations in atmospheric pressure

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Hypertensive Crisis (from enrollment to the end of follow up duration of 7 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-09-15
Completion: 2025-09-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 350 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Saglik Bilimleri Universitesi
Collaborators: Etimesgut Military Hospital
Principal Investigators:
  • Gulsen AKCAY, ass. prof. (STUDY_DIRECTOR) - Ankara Etlik City Hospital
Contact Information
Study Contact:
Gulsen AKCAY, Ass. Prof.
+905052874949
gulakcay@yahoo.com.tr
Elif HAMZACEBIOGLU KAYISOGLU, Specialist
+905453300679
turkuaz-61@indowslive.com
Gulsen AKCAY, Associate Professor
+905052874949
gulakcay@yahoo.com.tr
Etlik City Hospital
Interventions
N/A
Study Locations (1 sites)
Etlik City Hospital, Ankara, 06170 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: 1. Age 18 and above 2. Hypertensive crisis (systolic ≥180 and/or diastolic ≥110 mmHg) Exclusion Criteria: 1. Patients presenting with hypertensive emergency (those with end-organ damage) 2. Patients who have traveled to another city or district within the last 4 days 3. Pregnant patients
Conditions Anxiety, Post Traumatic Stress Disorder,...
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This project aims to improve mental health support for Venezuelan migrants living in Lima, Peru, who often face challenges like anxiety, depression, and post-traumatic stress disorder (PTSD). Since 2015, millions of Venezuelans have fled their country due to a severe humanitarian crisis, including extreme inflation, food shortages, and political unrest. Many of these individuals now live in Peru, where they struggle to access mental health services. A new type of intervention that is both evidence-based and culturally adapted to meet the specific needs of Venezuelan migrants is the focus of this research. The intervention is designed to be delivered by trained lay providers-people from the community who have received special training but are not professional mental health workers. The intervention consists of 6 to 12 weekly online sessions, each lasting about an hour. These sessions will cover various therapeutic techniques, including cognitive restructuring (changing negative thought patterns), behavioral activation (encouraging positive activities), and emotional regulation (managing feelings). The sessions will be conducted remotely, allowing participants to join from the comfort of their homes.This approach is intended to make mental health care more accessible and relatable for migrants, who may feel more comfortable receiving help from someone who understands their cultural background and experiences.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Adapted cognitive-behavioral (CBT) intervention — The intervention is 6-12 sessions, depending on the symptom presentation of the participant. The weekly sessions last 60 minutes and will be delivered remotely and individually via Meet or a similar platform by trained lay providers. Intervention methods include cognitive re-structuring, behavioral activation, exposure to memories and situations, problem solving, and emotional regulation.

Primary Outcomes

  • Anxiety (Throughout the study (on average 10 months for each participant). Outcome will be assessed every 2 weeks during the intervention (on average 3 months long), and after completion of the intervention at 1 month, 3 months, and 6 months follow-up)
  • Depression (Throughout the study (on average 10 months for each participant). Outcome will be assessed every 2 weeks during the intervention (on average 3 months long), and after completion of the intervention at 1 month, 3 months, and 6 months follow-up)
  • Post Traumatic Stress Disorder (PTSD) (Throughout the study (on average 10 months for each participant). Outcome will be assessed every 1 week during the intervention (on average 3 months long), and after completion of the intervention at 1 month, 3 months, and 6 months follow-up)
  • Traumatic Life Events (Throughout the study (on average 10 months for each participant). Outcome will be assessed every 2 weeks during the intervention (on average 3 months long), and after completion of the intervention at 1 month, 3 months, and 6 months follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-15
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Boston Medical Center
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Haley Carroll, PhD MS (PRINCIPAL_INVESTIGATOR) - Boston Medical Center, BUCA School of Medicine
Contact Information
Study Contact:
Haley Carroll, PhD MS
617 414 2035
hcarrol1@bu.edu
Interventions
  • Behavioral: Adapted cognitive-behavioral (CBT) intervention — The intervention is 6-12 sessions, depending on the symptom presentation of the participant. The weekly sessions last 60 minutes and will be delivered remotely and individually via Meet or a similar platform by trained lay providers. Intervention methods include cognitive re-structuring, behavioral activation, exposure to memories and situations, problem solving, and emotional regulation.
Study Locations (1 sites)
Universidad del Pacifico, Lima, Peru
Eligibility Criteria
Inclusion Criteria: To be eligible to participate in this study, an individual must meet all of the following criteria: * have Venezuelan nationality * have arrived in Lima in years 2014 to the present * be 18 years of age or older In addition, in order to be eligible to participate in this study, an individual must meet one of the following criteria: * score 10 points or more at the Patient Health Questionnaire (PHQ-9) or * score 10 points or more at the General Anxiety Disorder (GAD-7) or * have a history of trauma exposure as listed in the Life Events Checklist (LEC-5) and score 31 points or more in the PTSD Checklist (PCL-5) Exclusion Criteria: An individual is excluded from the study if they respond positively to one or more of the following questions during screening: * Suicidal ideation: "When someone feels as upset as you do, they may have thoughts that life isn't worth living. What thoughts have you had like this?" * Homicidal ideation: "When someone feels as upset as you do, they may have thoughts about hurting the person who has upset or hurt them. What thoughts have you had like this?" * Psychosis: "Do you have a diagnosis of psychosis or schizophrenia?"
Conditions Cardiovascular Diseases, Coronary Artery...
Phase Not Applicable
Enrollment 300
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The primary goal of this project is to develop a predictive model for clinically significant depressive symptoms (CSDS) in patients undergoing coronary artery bypass graft (CABG) surgery, using pre- and perioperative data. CSDS occur in about 30 percent of CABG patients, which is four times higher than in the general population. These symptoms are linked to poor quality of life and increased morbidity and mortality. The aim is to create a model that can identify patients at risk for postoperative depression. This tool could help clinicians make informed decisions and take preventive measures to manage depression after surgery.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Patient Health Questionnaire (PHQ-9) score ≥10 (yes/no) at 6 weeks post-CABG (Baseline (1 day before CABG surgery) and Follow Up (6 weeks after CABG surgery))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-11-25
Completion: 2027-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Roland von Känel
Collaborators: Triemli Hospital, ETH Zurich, University of Zurich
Principal Investigators:
  • Omer Dzemali, Prof. Dr. (PRINCIPAL_INVESTIGATOR) - Stadtspital Zürich Triemli, Klinik für Herzchirurgie, Birmensdorferstr. 497, 8063 Zurich, Switzerland
  • Roland v Känel, Prof. Dr. (PRINCIPAL_INVESTIGATOR) - University Hospital Zurich, Dept. of Consultation-Liaison Psychiatry, Haldenbachstr. 16/18, 8091 Zurich, Switzerland
Contact Information
Study Contact:
Roland v Känel, Prof. Dr.
+41 (0)44 255 52 51
roland.vonkaenel@usz.ch
Sinthujan Sivakumar, MSc
+41 (0)44 255 35 95
sinthujan.sivakumar@usz.ch
Héctor Rodríguez, Dr. med.
+41 43 253 26 87
hector.rodriguez@usz.ch
Stadtspital Zürich (City Hospital Zurich) Triemli
Interventions
N/A
Study Locations (2 sites)
Stadtspital Zürich (City Hospital Zurich) Triemli, Zurich, 8063 Switzerland
University Hospital Zurich (USZ), Zurich, 8091 Switzerland
Eligibility Criteria
Inclusion Criteria: * Elective Off-Pump CABG or CABG, either isolated or combined with valve intervention * Men and women, aged between 18 and 90 years * Sufficient knowledge of German language in reading and understanding * Oral and Signed consent form * Ability and Willingness to follow the study protocol Exclusion Criteria: * Cognitive impairment according to a score of ≤ 7 (maximum score = 9) on a modified version of a short version of the Mini-Mental State Examination and the Brief Interview for Mental Status * Any serious comorbid non-cardiac medical condition likely to cause death within 1 year (e.g. metastatic cancer) * Active psychotic symptoms (assessed with two items from the Youth Psychosis At Risk Questionnaire), substance abuse and/or dependence within the past 6 months (assessed with a single-item questionnaire), and/or active suicidal ideations (assessed with a single item from the M.I.N.I.). * Acute or emergency CABG
Conditions Anxiety, Depression
Phase NA
Enrollment 400
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Mental health problems and disorders affect one in every five amongst the working- age adults in the countries of the Organization for Economic Cooperation and Development. This constitutes a major public health challenge that also has large implications for work participation and productivity. Major depression and anxiety are the most prevalent of the mental disorders and are therefore named common mental disorders (CMD). CMD have become a major cause of work absenteeism, with 30% of all sick leave in Norway being due to CMDs in 2024. Early interventions addressing psychological aspects and vocational challenges related to work have shown a positive effect on return to work. Therefore, finding ways to increase availability and reduce barriers to evidence-based treatments seems a viable route to reducing mental health's impact on sick leave and absenteeism. Research show that improvement in symptoms from ordinary psychotherapy has little impact on sick-leave. The same results have been found for internet-based cognitive therapy (ICBT). One of the challenges in specialised mental health care is that the work focus has been an additive or extended part of the treatment, not integrated in the treatment itself. Several studies have been conducted on psychological treatments that specifically target return to work for people with CMDs. Systematic reviews have shown that work-focused therapy has a small, but significant effect over treatment as usual on return to work and finds that 20% more workers in the intervention groups had returned to work, compared to control groups. The availability of traditional therapy is scarce and there is an need for new effective ways of delivery. internet-based cognitive therapy has been shown to be as effective as traditional therapy in many systematic reviews and meta analysis and seems a good approach to reach the goal of increasing availability. To account for the heterogene group of people on sick leave the investigators have created a transdiagnostic, work-focused internet-based cognitive behaviloural therapy program. This study aims is to is to investigate the utility and use of this treatment program for patients with common mental health disorders on sick leave or work assessment allowance. This includes the user experience of participation and experienced utility of the treatment program.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Transdiagnostic, work-focused Cognitive Behavioural Therapy — Transdiagnostic, work-focused Cognitive Behavioural Therapy focuses on core mechanisms that creates and maintain illness in depression and anxiety. Namely reducing avoidance and/or suppression of unwanted thoughts, avoidance of meaningful activity and increase cognitive flexibility while under psychological stress.

Primary Outcomes

  • Degree of Sickleave (baseline, 6 weeks, 12 weeks, 6 months and 12 months)
  • Return to Work Self-efficacy 11 (baseline, 6 weeks, 12 weeks, 6 months and 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-01
Completion: 2028-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Solli Distriktspsykiatriske Senter
Collaborators: Sykehuset Innlandet HF, Sykehuset Ostfold, Sykehuset i Vestfold HF, University Hospital, Aker, Helse Fonna, Helse-Bergen HF, Vestre Viken Hospital Trust, Macquarie University, Australia, Diakonhjemmet Hospital, Haukeland University Hospital
Principal Investigators:
  • Pål William Wallace, PhD (STUDY_DIRECTOR) - Solli DPS
  • Kristine Sirevåg, MSc (STUDY_CHAIR) - Solli DPS
Contact Information
Study Contact:
Henning Monsen, MSc
0047+47018243
henning.monsen@Solli.no
Pål William Wallace, PhD
004745356200
pal.wiliam.wallace@solli.no
Mari Mathiesen, Master
+47 33333333
mari.barstad.mathiesen@vestreviken.no
Sykehuset Vestre Viken
Interventions
  • Behavioral: Transdiagnostic, work-focused Cognitive Behavioural Therapy — Transdiagnostic, work-focused Cognitive Behavioural Therapy focuses on core mechanisms that creates and maintain illness in depression and anxiety. Namely reducing avoidance and/or suppression of unwanted thoughts, avoidance of meaningful activity and increase cognitive flexibility while under psychological stress.
Study Locations (9 sites)
Sykehuset Vestre Viken, Oslo, Bærum 1346 Norway
Sykehuset Innlandet, Lillehammer, Innlandet 2609 Norway
Vinderen DPS, Oslo, Oslo 0373 Norway
AHus DPS Grorudalen, Oslo, Oslo 1067 Norway
Sykehuset i Vestfold, Tønsberg, Vestfold 3103 Norway
University of Bergen, Bergen, Vestland 5007 Norway
Bjørgvin DPS (Helse Bergen), Bergen, Vestland 5113 Norway
Solli DPS, Bergen, Vestland 5227 Norway
Sykehuset i Østfold, Fredrikstad, Østfold fylke 1603 Norway
Eligibility Criteria
Inclusion Criteria: 1. being an outpatient in specialised mental health care service, 2. above 18 years old, 3. full or graded sick leave, or on work assessment allowance 4. primary diagnosis of F30 - F40 (ICD-10), 5. currently employed. Exclusion Criteria: 1. ongoing psychotic disorder and/or mania, 2. ongoing substance abuse, incl. sedative medications, 3. ongoing episode of major depression, 4. organic brain disease, 5. severe reading and writing difficulties.
Conditions Bipolar I Disorder, Bipolar II Disorder
Phase PHASE2
Enrollment 195
Locations 33 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. This study will assess how safe and effective Icalcaprant is in treating adult participants with bipolar I or II disorder. Icalcaprant is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Participants are placed in 1 of 3 groups, called treatment arms. There is a 1 in 3 chance that a participant will be assigned to a placebo. Around 195 adult participants with bipolar I or II disorder will be enrolled in approximately 35 sites across the United States of America. Participants will receive oral capsules of Icalcaprant or matching placebo once daily for 6 weeks, with a 4-week safety follow-up period. There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Icalcaprant — Oral Capsules
  • Drug: Placebo for Icalcaprant — Oral Capsules

Primary Outcomes

  • Change from Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) total score (Up to approximately Week 6)
  • Number of Participants with Adverse Events (AEs) (Up to approximately 10 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-02-03
Completion: 2027-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 195 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AbbVie
Principal Investigators:
  • ABBVIE INC. (STUDY_DIRECTOR) - AbbVie
Contact Information
Study Contact:
ABBVIE CALL CENTER
844-663-3742
abbvieclinicaltrials@abbvie.com
Site Coordinator
2245347332
Pillar Clinical Research - Chicago /ID# 272823
Interventions
  • Drug: Icalcaprant — Oral Capsules
  • Drug: Placebo for Icalcaprant — Oral Capsules
Study Locations (33 sites)
University of Alabama - Huntsville Regional Medical Campus /ID# 272951, Huntsville, Alabama 35801 United States
Chandler Clinical Research Trials /ID# 274500, Chandler, Arizona 85224 United States
Del Sol Research Management - East Tanque Verde Road - Tucson /ID# 279767, Tucson, Arizona 85715 United States
Sanro Clinical Research Group /ID# 279462, Bryant, Arkansas 72022 United States
Advanced Research Center /ID# 272828, Anaheim, California 92805 United States
Collaborative Neuroscience Research - Garden Grove /ID# 271917, Garden Grove, California 92845 United States
Catalina Research Institute /ID# 272831, Montclair, California 91763 United States
Excell Research /ID# 272854, Oceanside, California 92056 United States
Pacific Neuropsychiatric Specialists - Orange /ID# 273118, Orange, California 92868 United States
Schuster Medical Research Institute /ID# 272848, Sherman Oaks, California 91403 United States
Eligibility Criteria
Inclusion Criteria: * Participants with a diagnosis of bipolar I or II according to the DSM-5-TR without psychotic features, confirmed by the MINI 7.0.2, and currently experiencing an MDE beginning at least 4 weeks prior to consent and not exceeding 12 months prior to Screening. * Body Mass Index (BMI) is \>= 18.0 to ≤\<= 35.0 kg/m\^2. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG. * CGI-S-BP score of ≥ 4 for depression and overall bipolar illness at screening (Visit 1) and baseline (Visit 2). * YMRS total score \<= 12 at screening (Visit 1) and baseline (Visit 2). * Participants on treatment with a single mood stabilizer (lithium, valproate, or lamotrigine), maintained at a stable dose for \>= 28 days prior to screening. Current mood stabilizer dose must remain unchanged for the duration of the study. * If taking lithium or valproate, participant must have a therapeutic blood level at screening of lithium (0.4 - 1.2 mg/dL) or valproate (50 - 125 mg/dL). * If taking lamotrigine, participant should be taking a dose within the FDA accepted range (50-400 mg/day, target dose is 200 mg/day) and investigator clinical judgment determines that the dose the participant is taking is likely to prevent onset of mood episodes. Exclusion Criteria: * History of an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and/or other products in the same class. * History of or active medical conditions(s) that might interfere with the conduct of the study, confound the interpretation of the study results, or endanger the subject's well-being. This includes any unstable condition, history or evidence of malignancy (other than treated basal or squamous cell carcinoma), or any significant hematologic, endocrine, cardiovascular, respiratory, renal, hepatic, gastrointestinal, or neurological disorder (if there is a history of such disease but the condition has been stable for more than 1 year, does not require treatment with prohibited medications, and is judged by the investigator not to interfere with the participant's participation in the study, the participant may be included in the study).
Conditions Type 1 Diabetes Mellitus, Glucokinase-Ma...
Phase EARLY_PHASE1
Enrollment 27
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to understand the heart and blood sugar health benefits of using an adjunctive therapy to lower high insulin levels in people with type 1 diabetes. The investigators will also look at people with a specific type of diabetes called Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY) and those without diabetes to help interpret the results. The investigators will use a medication that helps the body get rid of sugar, called and SGLT2 inhibitor, with the goal to reduce the body's insulin requirements. The investigators believe this could lead to better heart and blood sugar health, including a better response to insulin and more available nitric oxide, a gas that helps blood vessels function well. The investigators will compare heart and blood sugar health risk factors in participants with type 1 diabetes, participants with Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY), and non-diabetic healthy volunteers under two conditions: high insulin levels typical of type 1 diabetes and normal insulin levels typical of the other two groups.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Procedure: Study Visit 1 — Hyperinsulinemic, euglycemic clamp and flow-mediated dilation (FMD) study. The study will randomize participants to first receive a five-hour intravenous insulin infusion to achieve normal plasma insulin concentrations (Eu-Ins) or higher plasma insulin concentrations (Hi-Ins)
  • Drug: Placebo — * T1DM participants in the Hi-Ins study will receive an oral placebo. During the Eu-Ins study they will receive an SGLT2i. * CGK-MODY participants and healthy volunteers will receive placebo in both studies.
  • Procedure: Study Visit 2 — Hyperinsulinemic, euglycemic clamp and flow-mediated dilation (FMD) study. Insulin levels infused during the five-hour insulin infusion will be opposite of the first visit.
  • Drug: Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor — Concurrent with starting the five-hour infusion, T1DM participants in the Eu-Ins study will receive an SGLT2i dose (empagliflozin 25 mg).

Primary Outcomes

  • Aim 1: Tissue glucose disposal (TGD) (8 hours)
  • Aim 2: Nitric Oxide (NO) bioavailability (8 hours)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2025-07-03
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 27 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vanderbilt University Medical Center
Principal Investigators:
  • Daniel J Moore, MD, PhD (PRINCIPAL_INVESTIGATOR) - Vanderbilt University Medical Center
Contact Information
Study Contact:
Daniel J Moore, MD, PhD
615-322-7427
metabolism@vumc.org
Daniel J Moore, MD, PhD
(615) 322- 7427
metabolism@vumc.org
Vanderbilt University Medical Center
Wendi Welch, CCRP
wendi.m.welch@vumc.org
Vanderbilt University Medical Center
Interventions
  • Procedure: Study Visit 1 — Hyperinsulinemic, euglycemic clamp and flow-mediated dilation (FMD) study. The study will randomize participants to first receive a five-hour intravenous insulin infusion to achieve normal plasma insulin concentrations (Eu-Ins) or higher plasma insulin concentrations (Hi-Ins)
  • Drug: Placebo — * T1DM participants in the Hi-Ins study will receive an oral placebo. During the Eu-Ins study they will receive an SGLT2i. * CGK-MODY participants and healthy volunteers will receive placebo in both studies.
  • Procedure: Study Visit 2 — Hyperinsulinemic, euglycemic clamp and flow-mediated dilation (FMD) study. Insulin levels infused during the five-hour insulin infusion will be opposite of the first visit.
  • Drug: Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor — Concurrent with starting the five-hour infusion, T1DM participants in the Eu-Ins study will receive an SGLT2i dose (empagliflozin 25 mg).
Study Locations (1 sites)
Vanderbilt University Medical Center, Nashville, Tennessee 37232 United States
Eligibility Criteria
Inclusion Criteria: Age: 18-60 years BMI: 18-28 kg/m² Weight: ≥ 50 kg T1DM Participants: Duration of T1DM: 1-30 years HbA1c: 5.7-7.5% Insulin Therapy: Using automated insulin delivery GCK-MODY Participants: HbA1c: 5.7-7.5% Genetic Confirmation: Positive GCK sequencing Control Participants: HbA1c: less than 5.5% \*\* Exclusion Criteria: Severe Hypoglycemia: ≥1 episode in the past 3 months Comorbidities: * Any hospital admissions for diabetic ketoacidosis in the past 6 months * SBP greater than 140 mmHg and DBP greater than 100 mmHg * eGFR by MDRD equation of less than 60 mL/min/1.73 m² * AST or ALT greater than 2.5 times ULN * Hct less than 35% Medications: * Any antioxidant vitamin supplement within 2 weeks before the study * Any systemic glucocorticoid * Antipsychotics * Atenolol, Metoprolol, Propranolol * Niacin * Any thiazide diuretic * Any oral contraceptive pill with greater than 35 mcg ethinyl estradiol * Growth hormone * Any immunosuppressant * Antihypertensive * Any antihyperlipidemic Other: * Pregnancy * Tanner stage less than 5 * Peri- or post-menopausal women * Active smoker T1DM Participants: Medications: Any diabetes medication except insulin C-peptide: greater than 0.7 ng/mL (fasting) GCK-MODY Participants: None specific
Conditions HR-positive,HER2-negative Breast Cancer
Phase PHASE2
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is the first to explore the clinical study of neoadjuvant radiotherapy followed by chemotherapy combined with terriplizumab in breast cancer. Participants with locally advanced (T1c-T2(≥2cm) N1-2M0 or T3-4cN0-2M0) HR-positive and HER2-negative breast cancer were enrolled to evaluate the efficacy and safety of neoadjuvant radiotherapy followed by chemotherapy combined with triplimab in the treatment of locally advanced HR-positive and HER2-negative breast cancer. About 30 participants are planned to participate in this clinical study.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: TORIPALIMAB INJECTION(JS001 ) — Drug A: 240mg intravenous infusion of Toripalimab, once every 3 weeks, the first dosing date was C1D1, followed by the first day of each course for 18 cycles, a total of 1 year. Drugs B and C: Epirubicin was administered intravenously after the dosage was calculated at 90mg/m2 body surface area, cyclophosphamide was calculated at 600mg/m2 body surface area by intravenous micropump, both drugs were administered every 3 weeks, the first administration date was C1D1, and then the first day of each course was administered for 4 cycles. Drug D:albumin paclitaxel was given intravenatically at a dose of 125mg/m2 body surface area, once a week, with the first administration date of C5D1, and then on the first day of each course for 12 cycles.
  • Radiation: Stereotactic Body Radiation Therapy (SBRT) — Local radiotherapy: Subjects received stereotactic radiotherapy for the primary breast cancer lesion at 8Gy each time for 3 consecutive days, once a day, 2 weeks before the start of systemic therapy

Primary Outcomes

  • Pathologic complete response(pCR) (Up to12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-07-01
Completion: 2028-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: First Affiliated Hospital of Zhejiang University
Principal Investigators:
  • Peifen Fu, MD (PRINCIPAL_INVESTIGATOR) - Zhejiang University
  • Senxiang Yan, MD (PRINCIPAL_INVESTIGATOR) - Zhejiang University
Contact Information
Study Contact:
Peifen Fu, MD
0571-87236852
fupeifen@zju.edu.cn
Peifen Fu, MD
0571-87236852
fupeifen@zju.edu.cn
the First Affiliated Hospital,Zhejiang University School of Medicine
Interventions
  • Drug: TORIPALIMAB INJECTION(JS001 ) — Drug A: 240mg intravenous infusion of Toripalimab, once every 3 weeks, the first dosing date was C1D1, followed by the first day of each course for 18 cycles, a total of 1 year. Drugs B and C: Epirubicin was administered intravenously after the dosage was calculated at 90mg/m2 body surface area, cyclophosphamide was calculated at 600mg/m2 body surface area by intravenous micropump, both drugs were administered every 3 weeks, the first administration date was C1D1, and then the first day of each course was administered for 4 cycles. Drug D:albumin paclitaxel was given intravenatically at a dose of 125mg/m2 body surface area, once a week, with the first administration date of C5D1, and then on the first day of each course for 12 cycles.
  • Radiation: Stereotactic Body Radiation Therapy (SBRT) — Local radiotherapy: Subjects received stereotactic radiotherapy for the primary breast cancer lesion at 8Gy each time for 3 consecutive days, once a day, 2 weeks before the start of systemic therapy
Study Locations (1 sites)
the First Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003 China
Eligibility Criteria
Inclusion Criteria: 1. Age 18-75 years old, gender is not limited; 2. Histologically or pathologically confirmed non-specific invasive ductal carcinoma, histologically grade3, ER≥1%, HER2 negative, Ki-67\>20%; 3. T1c-T2(≥2cm)N1-2M0 or T3-4cN0-2M0; 4. No previous treatment; 5. ECOG PS 0-1 score; 6. The subject or legal representative has been informed of the nature of the study, understands the protocol, is able to guarantee compliance, and signs the informed consent Exclusion Criteria: 1. Those who are known to be allergic to recombinant humanized antiPD-1 monoclonal antibody drugs and their components; 2. Currently participating in and receiving other research treatment; 3. Previously received systematic treatment for breast cancer, including systematic chemotherapy, targeted therapy, immunotherapy, etc.; 4. Remote metastatic lesions of breast cancer were confirmed by imaging or pathology; 5. Patients with active tuberculosis (TB) who are receiving anti-TB therapy or have received anti-TB therapy within 1 year prior to screening; 6. Uncontrolled or symptomatic hypercalcemia (\&gt; 1.5mmol/L calcium ion or calcium \&gt; 12mg/dL or corrected serum \&gt; ULN); 7. Clinically uncontrolled active infections, including but not limited to acute pneumonia; 8. Uncontrollable major seizures or superior vena cava syndrome; 9. previous or current co-occurrence of other malignant tumors (except for non-melanoma skin basal cell carcinoma or squamous cell carcinoma, breast/cervical carcinoma in situ, superficial bladder carcinoma and other in situ cancers that have been treated radically and have no evidence of disease recurrence); 10. Have a history of interstitial pneumonia, idiopathic pulmonary fibrosis, institutional pneumonia (such as bronchiolitis obliterans), drug-induced pneumonia, idiopathic pneumonia, chest CT screening found evidence of active pneumonia or other moderate to severe lung diseases that seriously affect lung function; 11. Known human immunodeficiency virus (HIV) infection (known HIV antibody positive); 12. Severe cardiovascular disease, such as New York Heart Association (NYHA) grade 2 or higher heart failure, unstable angina, unstable arrhythmia, myocardial infarction or cerebrovascular accident within the first 6 months of enrollment; 13. received systemic immunosuppressive drugs (i.e. use of corticosteroids or immunosuppressive drugs) for any active autoimmune disease within 2 years prior to study initiation; 14. Received live virus vaccine within 4 weeks prior to study initiation; 15. Patients who have previously received allogeneic stem cells or parenchymal organ transplants; 16. Pregnant or lactating women or women who have the possibility of becoming pregnant have tested positive for pregnancy before the first drug use, and patients who are fertile but do not want to take contraceptive measures or their sexual partners do not want to take contraceptive measures 17. Any other clinically significant illness or condition that the investigator believes could affect adherence to the protocol (such as a history of mental illness or substance abuse), prevent the patient from benefiting from the clinical study, or prevent the patient from signing informed consent (such as drug use and substance abuse), or make participation in the clinical study inappropriate (including but not limited to: Abnormal laboratory results, clinical active diverticulitis, abdominal abscess, intestinal obstruction, and peritoneal metastases).
Conditions Type 2 Diabetes Mellitus (T2DM), Pregnan...
Phase NA
Enrollment 564
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if continuous glucose monitoring works better than self-monitoring of blood glucose (fingersticks) to treat type 2 diabetes in pregnancy. It will also learn about all risk factors (biologic, personal, social) for maternal and infant complications in type 2 diabetes pregnancies. The main questions it aims to answer are: 1. Does continuous glucose monitoring improve infant outcomes compared to self-monitoring of blood glucose? 2. Does continuous glucose monitoring improve maternal diabetes control and other maternal outcomes compared to self-monitoring of blood glucose? 3. What other factors increase the risk of maternal and infant complications? Participants will: 1. Use continuous glucose monitoring or self-monitoring of blood glucose to monitor blood sugar control from enrollment until delivery 2. Have blood drawn at enrollment, 24 weeks, 34 weeks and delivery to measure hemoglobin A1c levels and store blood for future analysis 3. Complete surveys about social support, environmental stressors, diabetes distress and glucose monitoring satisfaction at research visits 4. Have umbilical cord blood collected at delivery for analysis

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: CGM — Real-time continuous glucose monitoring

Primary Outcomes

  • Time in Range (TIR) at 34 weeks gestation (33 to 35 weeks gestation)
  • Composite Neonatal Morbidity (From the date of delivery to the date of neonatal hospital discharge, assessed up to 12 months of life)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-08
Completion: 2029-07
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 564 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alabama at Birmingham
Collaborators: National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Principal Investigators:
  • Ashley Battarbee, MD, MSCR (PRINCIPAL_INVESTIGATOR) - University of Alabama at Birmingham
Contact Information
Study Contact:
Ashley Battarbee, MD, MSCR
205-975-2361
anbattarbee@uabmc.edu
Ashley Battarbee
205-975-2361
anbattarbee@uabmc.edu
University of Alabama at Birmingham
Gladys Ramos, MD
858-657-7200
gramos@health.ucsd.edu
University of California at San Diego
Interventions
  • Device: CGM — Real-time continuous glucose monitoring
Study Locations (7 sites)
University of Alabama at Birmingham, Birmingham, Alabama 35233 United States
University of California at San Diego, San Diego, California 92121 United States
University of North Carolina - Chapel Hill, Chapel Hill, North Carolina 27599 United States
Oregon Health and Science University, Portland, Oregon 97213 United States
University of Pennsylvania, Philadelphia, Pennsylvania 19104 United States
Prisma Health Greenville Memorial Hospital, Greenville, South Carolina 29605 United States
University of Texas Health Science Center at Houston, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * Type 2 diabetes mellitus treated with daily insulin injections or oral hypoglycemic agents diagnosed before pregnancy or at less than 14 weeks gestation with hemoglobin A1c 6.5% or greater * Pregnant with viable fetus at 6 to less than 23 weeks gestation * Maternal age 18-50 years old Exclusion Criteria: * Unable or unwilling to wear CGM due to intolerance to medical-grade adhesives or skin conditions * Multiple gestation * Major fetal anomaly or two or more minor fetal anomalies * Planned delivery outside study consortium * Participating in another conflicting interventional study * Participation in this trial in a previous pregnancy * Patient unable to consent * Physician refusal for other reasons
Conditions Mastectomy; Lymphedema, Breast Cancer
Phase PHASE4
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose this research is to compare two different standards of care for pain management and two different standards of care for local numbing medicine for breast cancer patients who will have a total mastectomy.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Sequential Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Drug: Bupivacain — Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle of 30 cc of 0.5% bupivacaine after mastectomy completion and prior to reconstruction, if performed, or wound closure.
  • Drug: Exparel — Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle of 20 cc of Exparel mixed with 10 cc of 0.5% bupivacaine after mastectomy completion and prior to reconstruction, if performed, or wound closure.
  • Procedure: Intraoperative Pecs II block (IOB) & superior AT (EX or BP) — Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle with superior anesthetic as determined by stage I, after mastectomy completion and prior to reconstruction, if performed, or wound closure.
  • Procedure: Preoperative Pecs II block (POB) & superior AT (EX or BP) — Preoperative Pecs II block to be administered by 1 of 6 acute pain specialized anesthesiologists in same day surgery. Patient will be lightly sedated with midazolam, at the discretion of the anesthesiologist. The pecs II block will be performed under ultrasound guidance using a 21-gauge, 80 mm length needle to administer the superior anesthetic as determined in stage I.

Primary Outcomes

  • Postoperative pain as indicated by postoperative opioid use via total inpatient and outpatient opioid use (oral morphine milliequivalents) (14 days post-operation)
  • Postoperative pain as indicated by postoperative opioid use discontinuation (14 days post-operation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-09-25
Completion: 2026-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Cincinnati
Contact Information
Study Contact:
UCCC Clinical Trials Office
513-584-7698
cancer@uchealth.com
Alicia Heelan, MD
Alicia Heelan, MD
University of Cincinnati Medical Center
Interventions
  • Drug: Bupivacain — Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle of 30 cc of 0.5% bupivacaine after mastectomy completion and prior to reconstruction, if performed, or wound closure.
  • Drug: Exparel — Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle of 20 cc of Exparel mixed with 10 cc of 0.5% bupivacaine after mastectomy completion and prior to reconstruction, if performed, or wound closure.
  • Procedure: Intraoperative Pecs II block (IOB) & superior AT (EX or BP) — Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle with superior anesthetic as determined by stage I, after mastectomy completion and prior to reconstruction, if performed, or wound closure.
  • Procedure: Preoperative Pecs II block (POB) & superior AT (EX or BP) — Preoperative Pecs II block to be administered by 1 of 6 acute pain specialized anesthesiologists in same day surgery. Patient will be lightly sedated with midazolam, at the discretion of the anesthesiologist. The pecs II block will be performed under ultrasound guidance using a 21-gauge, 80 mm length needle to administer the superior anesthetic as determined in stage I.
Study Locations (1 sites)
University of Cincinnati Medical Center, Cincinnati, Ohio 45219 United States
Eligibility Criteria
Inclusion Criteria: * Patients who are 18 years of age or older * Patients undergoing mastectomy with or without axillary surgery, with or without reconstruction surgery at UCMC for breast cancer or high-risk of breast cancer. Patients with high-risk of breast cancer are those who have atypical/precancerous breast lesion(s), genetic mutation with increased risk of cancer (e.g., BRCA1, BRCA2 etc..) and/or a strong family history of breast cancer in the opinion of the investigator. Exclusion Criteria: * Patients undergoing only a partial mastectomy or tissue-based reconstruction. * Non-English speaking. * Patients who are pregnant. * Patients with an allergy to local anesthetics * Except: patients with allergies only to topical anesthetics may be included. * Patients with a preoperative acute or chronic pain disorder with an opioid prescription that has been prescribed within 30 days of surgery. Patients who have not filled such a prescription or who state they have not taken the medications prescribed, may be eligible on a case-by-case basis per investigator judgement. * Patients with a history of opioid use disorder. * Inability to provide informed consent. * Patients who otherwise in the opinion of the Investigator are not good candidates for participation (e.g., deemed unreliable for follow-up).
Conditions Breast Cancer, Ductal Carcinoma in Situ,...
Phase PHASE2
Enrollment 47
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In the management of early breast cancer patients, postoperative radiotherapy following breast-conserving surgery has been established as the standard treatment. Over the past two decades, significant changes have occurred in radiotherapy for breast cancer, encompassing dose fractionation methods, radiotherapy techniques, and delineation of the radiation field. Hypofractionated radiotherapy has been reported in numerous randomized phase 3 studies to show equivalent tumor control rates, reduced acute side effects, and similar late side effects compared to conventional fractionation. Among hypofractionated radiotherapy approaches, particularly in early-breast cancer, accelerated partial breast irradiation (APBI) may be chosen over whole breast irradiation (WBI). This approach is based on data indicating that the majority of local recurrences in breast cancer occur around the site of the primary tumor. By targeting radiation to the involved breast region, it becomes possible to increase the dose per fraction while shortening the overall treatment duration due to the smaller radiation treatment volume. While careful patient selection is crucial, multiple clinical studies have demonstrated that APBI, particularly after breast-conserving surgery, yields satisfactory local control rates comparable to WBI. This is accompanied by reduced side effects, improved convenience, enhanced quality of life, and potential cost savings. Traditionally, APBI has been administered after surgery, but there is a recent trend to explore preoperative APBI. The rationale for performing preoperative APBI includes several considerations. Firstly, compared to postoperative APBI, the precise location of visually identifiable tumors allows for more accurate and targeted radiation therapy, minimizing the impact on adjacent normal tissues and achieving superior cosmetic results. Secondly, reducing the size of the preoperative lesion may enable more conservative surgery, decreasing the extent of the surgical procedure. Thirdly, it can serve as a preparatory treatment to assess tumor responsiveness. Fourthly, in some cases, it may be administered for definitive purposes, especially in elderly or frail women who may find it challenging to undergo standard treatment due to concurrent health issues. Several clinical studies have reported the effectiveness and validity of preoperative PBI in a few cases of early breast cancer. These studies have shown low rates of acute and chronic toxicity, with excellent cosmetic outcomes. While accumulating evidence supports preoperative PBI, there is currently a lack of comparative studies with postoperative PBI. Therefore, this study aims to compare and evaluate the overall clinical advantages, including safety and efficacy, of preoperative PBI and postoperative PBI in early breast cancer patients.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Preoperative PBI — Preoperative PBI: 21 Gy \* 1 fraction Preoperative PBI is administered within 6 weeks of the patient's initial registration, and surgery is scheduled within 8 to 12 weeks after PBI.

Primary Outcomes

  • Rate of grade 2 or higher acute toxicities (Within 6 months after the start of radiotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-10-13
Completion: 2026-10-12
Eligibility
Age: 45 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 47 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yonsei University
Principal Investigators:
  • Yong Bae Kim (PRINCIPAL_INVESTIGATOR) - Department of Radiation Oncology, Yonsei University College of Medicine
Contact Information
Study Contact:
Yong Bae Kim
82-2-2228-8106
ybkim3@yuhs.ac
Yong Bae Kim
ybkim3@yuhs.ac
Department of Radiation Oncology, Yonsei University College of Medicine
Interventions
  • Radiation: Preoperative PBI — Preoperative PBI: 21 Gy \* 1 fraction Preoperative PBI is administered within 6 weeks of the patient's initial registration, and surgery is scheduled within 8 to 12 weeks after PBI.
Study Locations (1 sites)
Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, South Korea
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed ductal carcinoma in situ (DCIS) and invasive breast cancer. * Age ≥ 45 * cT1/cN0, tumor size ≤ 2.5cm * ECOG 0\~2 -ER+, HER2- Exclusion Criteria: * cN+ * Tumor located too close to the skin or chest wall (within 5 mm) * With previous treatment history for breast cancer * Neoadjuvant chemotherapy * Multicentric disease * Diffuse microcalcification * BRCA mutation * Paget's disease * In cases where tumor delineation is not achievable on CT/MRI images
Conditions Glaucoma, Glaucoma Open-Angle
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to evaluate the efficacy, transorbital alternating current stimulation (rtACS) using the EYETRONIC for the treatment in patients with glaucoma.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Eyetronic rtACS — The repetitive, transorbital alternating current stimulation (rtACS) is a device for non-invasive Interventional Neurophysiology. The electrical charge and current density applied during rtACS safe and able to modulate existing neuronal elements in the eye and brain.
  • Device: Sham rtACS — Participants will wear the Eyetronic system but there will be no active stimulations applied.

Primary Outcomes

  • Visual Field Index (VFI) (3 Months)
  • Mean Deviation (MD) (3 Months)
  • Pointwise Linear Regression (PLR) (3 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-14
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stanford University
Collaborators: EYETRONIC, Inc
Principal Investigators:
  • Jeffrey L Goldberg, MD PhD (PRINCIPAL_INVESTIGATOR) - Stanford University
Contact Information
Study Contact:
Study Team
650-497-5942
glaucomatrials@stanford.edu
Study Team
650-497-5942
zacwenn@stanford.edu
Byers Eye Institute at Stanford University
Jeffrey Goldberg, MD PhD
Byers Eye Institute at Stanford University
Interventions
  • Device: Eyetronic rtACS — The repetitive, transorbital alternating current stimulation (rtACS) is a device for non-invasive Interventional Neurophysiology. The electrical charge and current density applied during rtACS safe and able to modulate existing neuronal elements in the eye and brain.
  • Device: Sham rtACS — Participants will wear the Eyetronic system but there will be no active stimulations applied.
Study Locations (1 sites)
Byers Eye Institute at Stanford University, Palo Alto, California 94303 United States
Eligibility Criteria
Inclusion Criteria: * Participant must be at least 18. * Participant must has the ability to comply with the requirements of the study and complete the schedule of events (SOE). * Participant's clinical diagnosis must be consistent with primary open angle glaucoma (including but not limited to normal tension, low tension or general open angle) characterized by the following features: Mean deviation (MD) worse than -6 but better than -20 on reliable Humphrey Visual Field 24-2 testing * Participant's eye pressure must be clinically stable, with IOP \< 18. * If a participant has two eyes meeting study criteria, the worse eye as determined by visual field index (VFI) or patient preference, will be deemed includable. If both eyes qualify and have the same VFI, the patient may choose which eye they are willing to enter, or else a randomization procedure will assign one eye to the study. * Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety. Exclusion Criteria: * Participant is unable to comply with study procedures or follow-up visits. * Participant has a history of ocular herpes zoster. * Participant has a requirement of acyclovir and/or related products during study duration. To be eligible for this study, the participant must discontinue use of these products prior to enrollment and must not continue with the products until after they have completed the study. * Participant has evidence of corneal opacification or lack of optical clarity. * Participant has uveitis or other ocular inflammatory disease. * Participant is receiving systemic steroids or other immunosuppressive medications. * Participant is currently participating in or has within the last 3 months participated in any other clinical trial of a drug by ocular (if in the study eye) or systemic administration. * Participant is pregnant or lactating. * Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments. * Patients with opened skull, after trepanation or with heart and brain pacemaker. * Patients with implanted intracranial metals such as clippings, coilings, ventriculo-peritoneal shunts, endoprosthesis etc. * Patients with any skin damage in the area of electrode placement. * Children and comatose patients. * Patients with recent history of epileptic seizure. * Patients with uncontrolled high levels of blood pressure (\<160 mmHg) or uncontrolled high levels of intraocular pressure (\<27 mmHg). * Patients abusing drugs or alcohol.
Conditions Pulmonary Arterial Hypertension
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to explore the safety and efficacy of the FreeFlow percutaneous atrial septal shunt for treatment of idiopathic pulmonary arterial hypertension. The main questions it aims to answer are: * Is the FreeFlow percutaneous atrial septal shunt safe to use in patients with idiopathic pulmonary arterial hypertension? * Does the FreeFlow percutaneous atrial septal shunt reduce all-cause mortality and readmission in patients with idiopathic pulmonary arterial hypertension, and how effective is it? Thirty subjects who met the inclusion and exclusion criteria were selected for selective implantation of FreeFlow percutaneous atrial septal shunts after balloon atrial septostomy. Participants will: * underwent balloon atrial septostomy and FreeFlow percutaneous atrial septal shunt implantation. * will be followed up at 24 hours after shunt implantation or before discharge, 1 month, 3 months, 6 months and 12 months.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: FreeFlow percutaneous atrial septal shunt — The trial devices included a percutaneous atrial septal shunt and an atrial septal shunt delivery system. The specifications of the atrial septal shunt device were -φ5, φ7, φ9, φ11, and the specifications of the atrial septal shunt delivery system-FFISS-B were 9F and 10F.

Primary Outcomes

  • All-cause mortality at 6 months (6 months)
  • Rehospitalization rates associated with exacerbation of pulmonary arterial hypertension (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-11
Completion: 2027-09-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Zhongshan Hospital
Principal Investigators:
  • Junbo GE, Prof. (PRINCIPAL_INVESTIGATOR) - Fudan University
Contact Information
Study Contact:
Daxin ZHOU, Prof.
13801641252
zhou.daxin@zs-hospital.sh.cn
Dandan CHEN, Prof.
13788926105
chen.dandan@zs-hospital.sh.cn
Dandan CHEN, Dr
+8613788926105
chen.dandan@zs-hospital.sh.cn
180 Fenglin Road
Interventions
  • Device: FreeFlow percutaneous atrial septal shunt — The trial devices included a percutaneous atrial septal shunt and an atrial septal shunt delivery system. The specifications of the atrial septal shunt device were -φ5, φ7, φ9, φ11, and the specifications of the atrial septal shunt delivery system-FFISS-B were 9F and 10F.
Study Locations (1 sites)
180 Fenglin Road, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: * 18≤ age ≤70 years old, female or male; * 10 mmHg≤ mean right atrial pressure (mRAP) ≤20 mmHg; * The subjects had severe idiopathic pulmonary hypertension (mean pulmonary arterial pressure \> 45 mmHg); * WHO grade III or IV; * NT-proBNP≥650 ng/L; * The subjects were informed of the nature of the study and agreed to all the requirements for participating in the study. They signed the informed consent form and agreed to complete the follow-up and the examinations required for the follow-up. Exclusion Criteria: * Local or systemic sepsis or other acute infection; * Severe coagulopathy; * Allergy to nickel and/or titanium and/or nickel/titanium-based materials; * Patients with contraindications to antiplatelet, coagulant or thrombotic therapy; * Intolerance to contrast media; * Have participated in other drug or device clinical trials during the same period; * Glomerular filtration rate (GFR) \< 50 mL/min; * Patients with severe liver dysfunction (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 3 times the upper limit of normal); * The patient had malignant arrhythmia; * The patient did not receive standardized drug therapy (triple sequential therapy) according to the Chinese guidelines for the diagnosis and treatment of pulmonary hypertension within 3 months; * Women who are pregnant, planning to become pregnant (within 12 months) or breastfeeding; * Severe restrictive or obstructive lung disease; * Implanted atrial septal defect (ASD)/ patent foramen ovale (PFO) closure device; * Left ventricular ejection fraction (LVEF) \<50%; * SpO2 \< 90% without oxygen inhalation (pulse measurement); * The anatomical structure of the heart is abnormal, and the shunt cannot be implanted on the atrial septum; * Other circumstances in which the patient was deemed by the investigator to be ineligible for inclusion in the trial.